News

Dr. Vaughan Clift, Ampio’s Chief Regulatory Officer explained "The seven (7) patient ‘open label’ phase of the 47 patient STRUT study was performed to assure that multiple injections

Under the settlement agreement, the company will pay the amount in a series of tranches through August 2015. The litigation is related to how the company has historically

The new agreements were based on the existing strategic partnership, which includes an oncology research program and co-location of AstraZeneca scientists at the Cancer Research UK Cambridge Institute.

Lymphoseek (technetium Tc 99m tilmanocept) is now indicated for lymphatic mapping using a handheld gamma counter to locate lymph nodes draining a primary tumor site in patients with

The research program is aimed at accelerating the advancement of an SVP immunotherapy designed to reset the immune system and restore tolerance to substances (antigens) that cause the

The acquisition is part of an ongoing collaboration and option agreement signed by the two companies in November 2012. As part of the acquisition, MorphoSys now has lanthipeptide

As announced on 2 October, 2014 Prima has reached an agreement to acquire Immutep subject to obtaining shareholder approval at its AGM to increase its share placement capacity

The U.S. patent No. 8,778,899, was granted for "Methods of Inducing Regulated Pancreatic Hormone Production in Non-pancreatic Islet Tissues" and recognizes the pioneering work done by Dr. Sarah

The newly issued patents expand the already large intellectual property estate surrounding BMP-7, which include over 450 issues and pending patents, and extends important intellectual property in OA